Healthcare waste in the United States is now estimated at roughly $1.6 trillion annually — a figure large enough to rival the GDP of major global economies. Yet unlike other trillion-dollar sectors, this one operates without a single point of accountability. It is embedded within contracts, claims systems, rebate structures, and administrative layers that diffuse responsibility so effectively that inefficiency has become normalized.
The scale is not speculative. A widely cited 2019 study published in JAMA estimated that between $760 billion and $935 billion of annual U.S. healthcare spending could be classified as waste, identifying administrative complexity, pricing failures, overtreatment, and fraud among the largest contributors. Since that analysis, overall national health expenditures have climbed toward $5 trillion per year. As total spending has grown, so too has the likely dollar value of embedded inefficiency.
What distinguishes healthcare waste is not merely its size, but its persistence. In most industries, cost anomalies trigger audit cycles, procurement reviews, and shareholder scrutiny. In healthcare purchasing, particularly within employer-sponsored plans, rising costs have often been treated as actuarial inevitabilities rather than management failures.
The Architecture of Diffused Accountability
More than 160 million Americans receive coverage through employer-sponsored health plans, many of them self-insured. Under the Employee Retirement Income Security Act (ERISA), these employers are fiduciaries, legally obligated to act prudently and solely in the interest of plan participants. In practice, however, responsibility for spending flows across insurers, third-party administrators, brokers, consultants, and pharmacy benefit managers — each operating within distinct contractual frameworks.
Over time, that specialization has produced complexity. Compensation models tied to transaction volume or drug pricing benchmarks can obscure true net costs. Rebate arrangements may be negotiated but not fully transparent. Claims audits are frequently retrospective and sample-based rather than continuous and comprehensive. The result is a system in which no single actor is structurally positioned to manage aggregate waste in real time.
In recent years, litigation against large employers over alleged mismanagement of health plan assets has increased, particularly around pharmacy benefit arrangements and excessive administrative fees. Plaintiffs have argued that plan sponsors failed to exercise adequate oversight of third-party vendors, raising questions about how fiduciary standards apply in increasingly complex contracting environments. At the same time, regulatory scrutiny has intensified under the Consolidated Appropriations Act, which expanded transparency requirements for broker compensation and pharmacy reporting. While outcomes vary, the broader signal is clear: healthcare purchasing is moving from a back-office benefits function toward an area of legal and financial accountability.
“It is not that no one is involved,” said Jude Odu, founder of Health Cost IQ and author of upcoming book Model Optimal Care. “It is that responsibility is fragmented. When accountability is distributed across too many intermediaries, inefficiency can persist without being directly confronted.”
Data Exists. Management Lags.
The technological argument for opacity is weakening. Federal hospital and insurer price transparency rules now require the publication of machine-readable rate data. Advanced claims analytics platforms can review 100 percent of transactions rather than limited samples. Artificial intelligence tools are capable of identifying billing irregularities, detecting emerging high-cost conditions, and benchmarking provider performance at scale.
In other words, visibility is increasingly possible.
“Access to data is not the same as managing it,” Odu said. “Dashboards do not create accountability. Governance does.”
In Model Optimal Care, Odu outlines a framework designed specifically for self-insured health plans, integrating payment integrity review, pharmacy cost analysis, and continuous claims monitoring under clearer oversight standards. The emphasis, he maintains, is operational discipline rather than technological novelty. “The tools are available,” he said. “The missing piece is consistent application.”
The economic implications extend beyond corporate balance sheets. If even a portion of the hundreds of billions in potentially recoverable waste identified in prior national analyses were systematically addressed within employer-sponsored plans, the effects would reverberate through wages, hiring capacity, and capital allocation decisions.
But the central question is not macroeconomic. It is managerial.
At $1.6 trillion, healthcare waste is not a marginal inefficiency; it is a structural feature of a multitrillion-dollar system. The mechanisms that sustain it are complex but visible. The analytics required to identify it are increasingly mature. What remains unresolved is who, precisely, will treat it as a governed financial responsibility rather than an unavoidable cost of doing business.
Until that question is answered, the trillion-dollar problem will remain not only measurable — but largely unmanaged.
